Drugs Archives – Treatment Action Group

2024 CROI Tuberculosis Research Round Up

March 14, 2024
Dorrit Walsh

Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands

July 13, 2023
Dorrit Walsh

After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...

Covers of the two nitrosamines publications on this page.

Nitrosamines and TB Medicines Information Note and Patient FAQs

April 19, 2023
Dorrit Walsh

In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…

The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic

March 28, 2023
Dorrit Walsh

The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.

Open Letter: Urgent Action Necessary to Improve Equitable Access to Bedaquiline-Based Regimens and Achieve 1/4/6×24

January 13, 2023
Dorrit Walsh

TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…

Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

November 16, 2022
Dorrit Walsh

Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.

image that reads: Introduction: 1/4/6 x24 - a campaign to rally energy, political will & funding to end TB

1/4/6×24 Community Campaign Training Materials

November 11, 2022
Dorrit Walsh

Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…

Storytelling to Support TB Preventive Treatment (TPT)

October 24, 2022
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.